Between 2021 & 2024, 2.3% Of Eligible Consumers With Obesity Were Prescribed A GLP-1 Medication

About 2.3% of adults with obesity have been prescribed semaglutide (Wegovy) or tirzepatide (Zepbound) glucagon-like peptide-1 (GLP-1) medications for obesity. The FDA approved Wegovy in June 2021 as a stand-alone treatment for weight loss, and Zepbound was approved for weight loss in October 2023. The medications are intended for use by people with a body mass index (BMI) of 30 or a BMI of 27 or greater if the person has at least one obesity-related comorbidity. The researchers said the low prescription rate likely indicates system-level access barriers and consumer-level demand barriers . . .